Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

1.7K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
1.7K
Cross-bridge Cycle01:26

Cross-bridge Cycle

108.7K
As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
108.7K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

801
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
801
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

25
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
25
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

2.2K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
2.2K
Alterations in Muscle Tone ll01:12

Alterations in Muscle Tone ll

25
Alterations in muscle tone are common manifestations of neurological disorders and reflect dysfunction within different nervous system regions. Spasticity, paratonia, and dystonia represent distinct forms of hypertonia, each with unique mechanisms, clinical features, and diagnostic importance.CharacteristicsSpasticity happens from upper motor neuron lesions and is characterized by velocity-dependent resistance to passive movement. Clinical features include:Exaggerated deep tendon reflexesClonus...
25

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plasma EV Proteomics Identifies ECM Remodeling and Inflammatory Proteins LUM and C7 as Candidate Biomarkers in FSHD.

Annals of clinical and translational neurology·2026
Same author

Late-onset facioscapulohumeral muscular dystrophy defines a distinct clinical subgroup.

Neuromuscular disorders : NMD·2026
Same author

Electrical Impedance Myography Detects Disease Progression over 12 to 24 Months in Facioscapulohumeral Muscular Dystrophy.

Annals of neurology·2026
Same author

A randomized, double-blind, placebo-controlled study of losmapimod in patients with facioscapulohumeral muscular dystrophy: Results of the REACH study.

Journal of neuromuscular diseases·2026
Same author

Shared burden of ultra-rare genetic variants across a spectrum of motor neuron diseases.

Translational neurodegeneration·2025
Same author

Electrical impedance myography captures features of muscle structure measured by MRI and transcriptomic analysis in facioscapulohumeral muscular dystrophy.

Journal of neuromuscular diseases·2025

Related Experiment Video

Updated: Apr 26, 2026

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis
08:16

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis

Published on: March 4, 2014

33.3K

Facioscapulohumeral muscular dystrophy.

Jeffrey Statland1, Rabi Tawil1

  • 1Department of Neurology, University of Rochester Medical Center, 265 Crittenden Boulevard, CU 420669, Rochester, NY 14642-0669, USA.

Neurologic Clinics
|July 20, 2014
PubMed
Summary

Facioscapulohumeral muscular dystrophy (FSHD) comprises FSHD1 and FSHD2, both causing progressive muscle weakness. Despite different genetic causes, they share a common mechanism, suggesting unified future therapies for this adult muscular dystrophy.

Keywords:
D4Z4 deletionDUX4Facioscapulohumeral muscular dystrophyMuscular dystrophySMCHD1 mutation

More Related Videos

Performing Human Skeletal Muscle Xenografts in Immunodeficient Mice
07:48

Performing Human Skeletal Muscle Xenografts in Immunodeficient Mice

Published on: September 16, 2019

9.6K
Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders
10:28

Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders

Published on: April 3, 2021

6.1K

Related Experiment Videos

Last Updated: Apr 26, 2026

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis
08:16

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis

Published on: March 4, 2014

33.3K
Performing Human Skeletal Muscle Xenografts in Immunodeficient Mice
07:48

Performing Human Skeletal Muscle Xenografts in Immunodeficient Mice

Published on: September 16, 2019

9.6K
Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders
10:28

Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders

Published on: April 3, 2021

6.1K

Area of Science:

  • Neurology
  • Genetics
  • Molecular Biology

Background:

  • Facioscapulohumeral muscular dystrophy (FSHD) is a prevalent adult-onset muscular dystrophy.
  • FSHD is clinically characterized by asymmetric, progressive muscle weakness, initially affecting facial, shoulder, and arm muscles.
  • Two main types, FSHD1 and FSHD2, are distinguished by their underlying genetic mutations.

Purpose of the Study:

  • To differentiate the genetic basis of FSHD1 and FSHD2.
  • To highlight the shared downstream molecular mechanisms between FSHD1 and FSHD2.
  • To underscore the potential for developing unified therapeutic strategies for all FSHD patients.

Main Methods:

  • Genetic analysis to identify mutations associated with FSHD1 and FSHD2.
  • Molecular pathway analysis to investigate common downstream mechanisms.
  • Clinical phenotyping to correlate genetic types with disease presentation.

Main Results:

  • FSHD1, representing 95% of cases, is linked to a deletion on chromosome 4q35.
  • FSHD2, comprising 5% of cases, lacks the specific 4q35 deletion.
  • Both FSHD types converge on a common downstream molecular pathway.

Conclusions:

  • FSHD1 and FSHD2, despite distinct genetic origins, share a common pathophysiological pathway.
  • This shared mechanism offers a promising target for developing future therapies effective for both FSHD types.
  • Understanding these commonalities is crucial for advancing treatment options for facioscapulohumeral muscular dystrophy.